KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 0.45.

  • Pfizer's Equity Ratio rose 562.28% to 0.45 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.45, marking a year-over-year increase of 562.28%. This contributed to the annual value of 0.41 for FY2024, which is 543.26% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's Equity Ratio is 0.45, which was up 562.28% from 0.43 recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Equity Ratio peaked at 0.78 during Q4 2021, and registered a low of 0.39 during Q4 2023.
  • For the 5-year period, Pfizer's Equity Ratio averaged around 0.46, with its median value being 0.44 (2025).
  • In the last 5 years, Pfizer's Equity Ratio tumbled by 4152.23% in 2022 and then surged by 1493.97% in 2023.
  • Over the past 5 years, Pfizer's Equity Ratio (Quarter) stood at 0.43 in 2021, then rose by 13.95% to 0.49 in 2022, then dropped by 19.13% to 0.39 in 2023, then rose by 5.43% to 0.41 in 2024, then rose by 7.41% to 0.45 in 2025.
  • Its Equity Ratio was 0.45 in Q3 2025, compared to 0.43 in Q2 2025 and 0.44 in Q1 2025.